Stockreport

DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]

DiaMedica Therapeutics Inc.  (DMAC) 
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm Check Earnings Report
PDF CEO Dietrich Pauls highlighted ongoing progress for DM199, the lead product candidate, emphasizing its role as "a recombinant form of the naturally occurring human tiss [Read more]